Hansa Biopharma Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 1/6
Hansa Biopharma has a total shareholder equity of SEK-320.0M and total debt of SEK943.0M, which brings its debt-to-equity ratio to -294.7%. Its total assets and total liabilities are SEK940.7M and SEK1.3B respectively.
Wichtige Informationen
-294.7%
Verhältnis von Schulden zu Eigenkapital
SEK 942.95m
Verschuldung
| Zinsdeckungsgrad | n/a |
| Bargeld | SEK 553.54m |
| Eigenkapital | -SEK 319.96m |
| Gesamtverbindlichkeiten | SEK 1.26b |
| Gesamtvermögen | SEK 940.68m |
Jüngste Berichte zur Finanzlage
Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?
Sep 22
Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt
Apr 03Recent updates
Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Oct 20Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%
Aug 24Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%
Jul 23Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Jul 21Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package
Jun 21Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump
May 21Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates
Apr 05Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report
Feb 07Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing
Dec 28Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts
Oct 13Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?
Sep 22Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)
May 31Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt
Apr 03Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Feb 06Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023
Feb 01Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: HNSA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langfristige Verbindlichkeiten: HNSA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: HNSA has negative shareholder equity, which is a more serious situation than a high debt level.
Schulden abbauen: HNSA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilanz
Liquiditätsreserve-Analyse
Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.
Stabile Start- und Landebahn für Bargeld: HNSA has less than a year of cash runway based on its current free cash flow.
Vorhersage Cash Runway: HNSA has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 20.7% each year.